{"a":[{"_":"ASCO: Celcuity dares to dream of becoming $10B company after breast cancer win over Piqray","$":{"href":"/biotech/asco-10-billion-ambitions-celcuity-details-breast-cancer-win-over-piqray","hreflang":"en"}}]}

ConferencepositivePiqrayPositive

AI Analysis

Summary

Celcuity presented breast cancer clinical data at ASCO showing a favorable comparison versus Piqray, positioning itself as a potential $10B company competitor to Revolution Medicines' RAS pathway advancement.

Outcome Details

Celcuity presented breast cancer data showing a win over Piqray at ASCO annual meeting

Importance:6/10

Sentiment:

0.70

ASCO conferencebreast cancerclinical datacompetitive comparisononcology

Related Companies

$CELC $RVMD

Read the original article

Published by FierceBiotech on June 1, 2026 9:59 PM

Read Original